Year: 2025

Asia Broadband To Report Increased Gold and Silver Production and Gross Profit For The Third Quarter, As Gold and Silver Holdings Continue to Appreciate

Written by Customer Service on November 5, 2025. Posted in Dividend Reports And Estimates.

LAS VEGAS, Nov. 05, 2025 (GLOBE NEWSWIRE) — Asia Broadband Inc. (OTC: AABB) (“AABB” or the “Company”) is pleased to announce that the Company will be reporting its increased gold and silver production and gross profit for the period ending September 30th, as gold and silver forecasts continue to rise. Additionally, the Company has recently reviewed its substantial gold and silver holdings and their significant appreciation from the initial production values. Further details and the third quarter financial results will be announced next week. About Asia Broadband Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production of precious metals and the accumulation of physical gold holdings. The Company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate the expansion...

Building on strong results – preparing for the next growth cycle

Written by Customer Service on November 5, 2025. Posted in Public Companies.

COMPANY ANNOUNCEMENT no. 10/2025 Building on strong results – preparing for the next growth cycleCopenhagen, November 5, 2025 cBrain® (NASDAQ: CBRAIN) maintains the execution of its fundamental growth strategy, which is built on four pillars: 1. Developing individual large customers2. Taking positions in selected niches3. Building subscriptions4. Developing a partner channel Large CustomersIn Q3, cBrain secured its largest individual agreement in Denmark by signing a contract with Aarhus Municipality. Aarhus is Denmark’s second-largest city, and once fully implemented, the city is expected to have 20,000 users on the F2 platform. Additionally, cBrain signed an agreement with Kompetencesekretariatet to deliver a national F2-based grant management system for the Danish Secretariat for Competence Development. Within...

MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

Written by Customer Service on November 5, 2025. Posted in Earnings Releases And Operating Results.

MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November 19, 2025 ROCKVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its preliminary results for the third quarter ended September 30, 2025 and reiterated its 2025 revenue guidance. Preliminary Third Quarter Results and Recent HighlightsCore business revenue of $6.4 million in the third quarter of 2025. Strategic Platform License SPL Program-related revenue of $0.4 million in the third quarter of 2025. Total revenue...

Viewbix Intends to Acquire Innovative Quantum Computing Technologies Company, Quantum X Labs

Written by Customer Service on November 5, 2025. Posted in Public Companies.

Company Signed a Non-Binding Term Sheet for a security exchange between the parties Tel Aviv, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) — Viewbix Inc. (Nasdaq: VBIX) (“Viewbix” or the “Company”), a global developer of ad-tech innovative technologies, today announced the signing of a non-binding term sheet outlining the proposed terms for the acquisition of Quantum X Labs Ltd. (“Quantum X Labs” and the “Acquisition”). Under the terms of the term sheet, upon the closing of the Acquisition, Viewbix will acquire 100% of Quantum X Labs’ issued and outstanding share capital in exchange for the issuance of shares of the Company’s common stock and pre-funded warrants to purchase shares of the Company’s common stock on a pro-rate basis to Quantum X Labs’s shareholders. These securities issuable to Quantum X Labs’s shareholders upon the closing...

Nayax Announces Connect LATAM 2025 for Regional Customers

Written by Customer Service on November 5, 2025. Posted in Mergers And Acquisitions.

HERZLIYA, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX), a global commerce enablement, payments, and loyalty platform helping merchants scale their business, today announced that it is hosting Nayax Connect LATAM with its partner Integral Vending today for its customers in the region. The event will be hosted at the Live Aqua in Mexico City. In the conference, Nayax will announce its expansion plans for the region and that, as part of the expansion efforts, Nayax has signed a non-binding letter of intent and entered into exclusivity to acquire Integral Vending, its exclusive distribution partner in Mexico since 2015. The transaction, if completed, will transform a decade-long partnership into a strategic platform for continued expansion across Latin America and position Nayax to capture accelerating...

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Written by Customer Service on November 5, 2025. Posted in Earnings Releases And Operating Results.

Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of overall survival (OS) and progression-free survival (PFS) are expected in late Q1 2026. A new response in a third indication has been observed in the fifth and final dosing cohort of the Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody); no dose-limiting toxicities have been observed at any dose level and full topline data are now expected to be presented at a medical meeting in H1 2026. Based on previously reported responses in the CTX-8371 Phase 1 study, cohort expansions in patients with non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC), are expected to begin in Q4 2025. CTX-10726...

Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates

Written by Customer Service on November 5, 2025. Posted in Earnings Releases And Operating Results.

BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2025 ending September 30, 2025. Business Updates On October 23, 2025, the Company received $80 million in gross proceeds in a private placement, before deducting fees and other expenses. The financing includes an initial upfront funding of $80 million and up to an additional $80 million in gross proceeds if all Tranche A warrants are exercised, subject to the terms and conditions specified therein. Additional proceeds of $40 million may be received if all Tranche B warrants are exercised by cash payment upon the achievement of...

Plains All American Reports Third-Quarter 2025 Results and Announces Closing of Acquisitions Totaling 100% Equity Interest in EPIC

Written by Customer Service on November 5, 2025. Posted in Earnings Releases And Operating Results.

HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) — Plains All American Pipeline, L.P. (Nasdaq: PAA) and Plains GP Holdings (Nasdaq: PAGP) today reported third-quarter 2025 results and provided the following highlights and recent developments: Third-Quarter Results and HighlightsReported net income attributable to PAA of $441 million and net cash provided by operating activities of $817 million. Delivered solid Adjusted EBITDA attributable to PAA of $669 million. Exited the quarter with 3.3x leverage ratio, toward the low-end of our target range of 3.25x – 3.75x. In September, Plains successfully raised $1.25 billion in aggregate senior unsecured notes with proceeds allocated toward redeeming senior notes maturing in October 2025 and to partially fund recently announced acquisitions.Recent DevelopmentsOn October 31st, Plains...

Stack Capital Group Inc. Reports Q3-2025 Financial Results

Written by Customer Service on November 5, 2025. Posted in Earnings Releases And Operating Results.

TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX:STCK; TSX:STCK.WT.A; TSX:STCK.WT.B) today announced its financial results for the quarter ended September 30, 2025. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated. Financial SummaryBook Value per Share (“BVpS”) was $14.26 as at September 30, 2025, compared to $14.34 at June 30, 2025. Total Book Value stood at $188.7 million. During the quarter, the Company successfully raised $35 million through a private placement, further strengthening its capital position as it actively pursues opportunities across late-stage, high-growth private companies.Portfolio Company Highlights SpaceXValuation increased from US$350B to US$400B during the quarter. Successfully completed its 11th Starship test...

Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

Written by Customer Service on November 5, 2025. Posted in Earnings Releases And Operating Results.

FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved comparability report between LX2006 HEK and Sf9 manufacturing processes in November 2025, endorsing use of Sf9 final commercial manufacturing process to begin dosing patients in upcoming pivotal study LX2006 interim clinical data show clinically meaningful improvements across cardiac and neurologic measures of Friedreich ataxia, including left ventricular mass index and the modified Friedreich Ataxia Rating Scale Completed enrollment of LX2020 HEROIC-PKP2 Phase I/II trial with ten participants dosed; interim data from low-dose cohort reported and additional clinical data from high-dose cohorts on track for January 2026 $154 million equity...

Year: 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals